Generex Biotechnology announced it has been granted a China patent for its Ii-Key peptide vaccine technology, a vaccine currently in US clinical trials to prevent a recurrence of breast cancer. Generex said the patent covers both its platform technologies and Ii-Key-containing drug development compounds. Generex is “actively seeking” either joint venture or licensing partnerships for the vaccine, and it has already begun discussions with several large pharmas. More details...

Stock Symbol: (NSDQ: GNBT)